The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
January 09 2017 - 07:00AM
Lund January 9, 2017 - Active Biotech AB (Nasdag
Stockholm: ACTI) announces today that the European Patent
Office has decided to grant Active Biotech's patent application
covering tasquinimod for use in the treatment of multiple myeloma.
The patent will be granted as European Patent No. 3041472 on
February 1, 2017 and has a duration lasting until 2035.
For further information, please
contact:
Tomas
Leanderson, President & CEO
Tel: +46 46 19 20 95
Hans Kolam, CFO
Tel: +46 46 19 20 44
|
Active
Biotech AB
(Org.nr 556223-9227)
Box 724, 220 07 Lund
Tel: +46 46 19 20 00
|
About tasquinimod
Tasquinimod is an
immunomodulatory, anti-metastatic and anti-angiogenic compound that
affects the tumor's ability to grow and spread. The development of
tasquinimod has previously been focused on the treatment of
prostate cancer with clinical proof of concept and a good safety
profile shown in Phase 2 and 3 studies. Tasquinimod's
mechanism of action is broadly applicable as anti-tumor treatment
and very good results have been achieved in models for multiple
myeloma, a blood cancer with a high medical need. Active Biotech is
seeking a partner for the continued development of tasquinimod in
multiple myeloma.
Active Biotech
AB (publ) (Nasdag Stockholm: ACTI) is a
biotechnology company with focus on neurodegenerative/inflammatory
diseases and cancer. Laquinimod, an orally administered small
molecule with unique immunomodulatory properties, is in pivotal
Phase 3 development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in Phase 2 development for
the treatment of primary progressive multiple sclerosis and
Huntington's disease. Furthermore, commercial activities are
conducted for the tasquinimod, paquinimod and SILC projects. Please
visit www.activebiotech.com for more information.
This information is information
that Active Biotech AB is obliged to make public pursuant to the EU
Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 13.00 pm CET on January 9,
2017.
The European Patent Office grants
patent for tasquinimod for MM
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024